At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 08 Oct 2001 No-Development-Reported for Obesity in USA (Unknown route)
- 08 Oct 2001 No-Development-Reported for Type-2 diabetes mellitus in USA (Unknown route)
- 07 Jul 2000 Phase-I clinical trials for Obesity in USA (Unknown route)